Gelesis Holdings, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GLSHQ research report →
Companywww.gelesis.com
Gelesis Holdings, Inc. , a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management.
- CEO
- Alessandro Sannino
- IPO
- 2020
- Employees
- 93
- HQ
- Boston, MA, US
Price Chart
Valuation
- Market Cap
- $7.33K
- P/E
- -0.20
- P/S
- 0.45
- P/B
- -0.44
- EV/EBITDA
- -0.55
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -6.95%
- Op Margin
- -472.72%
- Net Margin
- -216.48%
- ROE
- 31.43%
- ROIC
- -137.49%
Growth & Income
- Revenue
- $25.77M · 130.37%
- Net Income
- $-57,128,000 · 39.05%
- EPS
- $-1.35 · 91.77%
- Op Income
- $-121,806,000
- FCF YoY
- -15.48%
Performance & Tape
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.62
- Avg Volume
- 5.47K
Get TickerSpark's AI analysis on GLSHQ
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our GLSHQ Coverage
We haven't published any research on GLSHQ yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GLSHQ Report →